No approved non-surgical gene therapy for hydrocephalus is available yet. A proof-of-concept study from the University of Cincinnati and University of California, Davis tested an adeno-associated virus (AAV) treatment in adult animal models. The therapy targeted choroid-plexus cells that make cerebrospinal fluid (CSF), reduced CSF production and limited fluid-related swelling in brain tissue.
The findings, published in Fluids and Barriers of the CNS and reported by News-Medical on October 14, 2026, are preclinical. They do not show that the treatment works in people, replaces a shunt, or can be obtained through regulated clinical care.
As an Amazon Associate I earn from qualifying purchases.
Why hydrocephalus still usually requires surgery
Hydrocephalus develops when CSF accumulates in and around the brain. Rising pressure can damage brain tissue and cause neurological impairment. The usual treatment is a shunt operation that diverts CSF to another part of the body, but shunts can fail and may require additional procedures.
Some neurosurgeons perform endoscopic partial cauterization of the choroid plexus, the tissue that produces much of the CSF. The News-Medical report says this approach can improve symptoms without substantially reducing total fluid volumes, and that technical and safety constraints make it unsuitable for many patients.
#1 Best Overall
How the experimental AAV treatment is intended to work
Targeting CSF-producing cells
The therapy uses an adeno-associated virus as a delivery vehicle for genetic instructions intended to target and reduce the activity or number of choroid-plexus cells that produce CSF. Lower production could reduce the amount of fluid spreading into brain tissue and ease the swelling associated with hydrocephalus.
Lead author Aleksandr Taranov, PhD, said the treatment “efficiently targets the correct cells and reduces CSF production.” The approach is therefore aimed at the source of excess fluid rather than relying solely on a mechanical drainage device.
A proposed route through an existing shunt
The investigators say delivery might eventually be possible through an existing shunt. Taranov described that as a way to make treatment “minimally invasive and feasible.” This is a proposed delivery concept, not an established procedure for patients. The study does not establish that the therapy can be administered through a human shunt or that it would eliminate the need for one.
Free tools Windows power users keep installed
One-click scans. No signup required.
Rank #2
What the animal study found
Adult models and blinded MRI analysis
UC Davis researchers Cameron Sadegh, MD, PhD, and Olga Chechneva, PhD, induced hydrocephalus in adult animal models and treated the animals with the experimental therapy. Treated models had less edema, meaning less excess fluid entering brain tissue outside the ventricles.
The Cincinnati team independently validated the findings with blinded MRI analysis. Blinding helps reduce the chance that expectations about treatment influence image assessment, but it does not turn an animal result into evidence of human benefit.
What the earlier work contributed
The project builds on a 2024 Proceedings of the National Academy of Sciences study from the Luo Lab. That work directly ablated adult choroid-plexus tissue and reduced CSF in adult animal models. The newer AAV strategy is intended to provide a cell-targeted way to achieve a related reduction in CSF production.
How this approach compares with current options
| Approach | Invasiveness and delivery | Evidence stage | Control of CSF production | Device dependence and availability |
|---|---|---|---|---|
| AAV gene therapy | Proposed delivery through an existing shunt; a patient procedure has not been established | Adult animal proof of concept | Designed to reduce CSF production by targeting choroid-plexus cells | Human use, device requirements and regulated availability have not been established |
| Shunt surgery | Invasive operation to divert CSF | Current clinical treatment | Drains CSF rather than directly reducing its production | Requires an implanted shunt; shunts can fail |
| Endoscopic partial choroid-plexus cauterization | Endoscopic brain procedure with technical and safety limitations | Used by some neurosurgeons | May improve symptoms without substantially reducing fluid volumes | Not technically or safely suitable for every patient |
There are no reported human, head-to-head outcomes comparing the AAV approach with shunts or endoscopic treatment. Duration of any CSF reduction and whether treatment would be disease-modifying remain unknown.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallWhy reducing CSF could also create risks
CSF is biologically important
CSF is not simply waste fluid. It supports the brain in several ways, so suppressing its production too aggressively could have consequences that are not visible in an initial pressure or imaging measurement.
An early developmental signal in animals
Initial animal testing found that loss of CSF production moderately reduced the brain’s ability to generate new neurons after birth in the hippocampus. The investigators say further work is needed to determine possible effects on neural networks and memory and to complete a risk-benefit analysis.
Those findings do not prove that the same effect would occur in people, but they are a reason the treatment cannot be treated as a simple substitute for drainage surgery. The study reports no human safety data, long-term outcomes or established dose for patients.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is the gene therapy available now?
No. The report describes no regulatory approval, human treatment result or active human clinical trial for this therapy. It is a preclinical animal-model study. A pending patent lists Luo and Taranov as inventors, but patent status does not establish clinical effectiveness or availability.
People with suspected or diagnosed hydrocephalus should continue to receive evaluation and treatment through a neurosurgical team. An experimental concept should not prompt anyone to delay urgent care, remove a shunt or seek an unregulated injection.
Best Value
What has to happen before human trials
The investigators identify larger-animal studies and testing in human tissues as the next steps, ideally followed by clinical trials. Those stages would need to address:
- whether the vector reaches the intended choroid-plexus cells reliably across different forms of hydrocephalus;
- how much CSF reduction is safe and how long it lasts;
- whether delivery through a shunt is practical and avoids additional invasive procedures;
- effects on brain development, neural networks, memory and other CSF-dependent functions; and
- manufacturing, monitoring and regulatory requirements for an AAV treatment.
As project scientist Olga Chechneva said, showing that choroid-plexus ablation reduces brain swelling also helps explain the mechanisms of hydrocephalus and the brain injury it causes. That mechanistic knowledge may be as important as the treatment concept itself. Luo characterized the work as “continuous,” underscoring that substantial development remains.
The practical answer for patients today
The study offers a credible direction for future therapy, not a current non-surgical option. Shunts and selected endoscopic procedures remain the clinically available approaches described in the report. The AAV strategy will need successful large-animal and human-tissue testing, followed by properly regulated human trials, before doctors can determine whether it is safer or more durable than existing care.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
